Literature DB >> 11253617

An identifiability analysis of a parent-metabolite pharmacokinetic model for ivabradine.

N D Evans1, K R Godfrey, M J Chapman, M J Chappell, L Aarons, S B Duffull.   

Abstract

The paper considers the structural identifiability of a parent-metabolite pharmacokinetic model for ivabradine and one of its metabolites. The model, which is linear, is considered initially for intravenous administration of ivabradine, and then for a combined intravenous and oral administration. In both cases, the model is shown to be unidentifiable. Simplification of the model (for both forms of administration) to that proposed by Duffull et al. (1) results in a globally structurally identifiable model. The analysis could be applied to the modeling of any drug undergoing first-pass metabolism, with plasma concentrations available from drug and metabolite.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11253617     DOI: 10.1023/a:1011521819898

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  1 in total

1.  A pharmacokinetic simulation model for ivabradine in healthy volunteers.

Authors:  S B Duffull; S Chabaud; P Nony; C Laveille; P Girard; L Aarons
Journal:  Eur J Pharm Sci       Date:  2000       Impact factor: 4.384

  1 in total
  15 in total

1.  A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine.

Authors:  Ophelia Q P Yin; Brian Tomlinson; Albert H L Chow; Moses S S Chow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Pharmacokinetic-pharmacodynamic modeling of the hydroxy lerisetron metabolite L6-OH in rats: an integrated parent-metabolite model.

Authors:  Fátima Ortega; Antonio Quintana; Elena Suárez; John C Lukas; Nerea Jauregizar; Leire de la Fuente; Maria Luisa Lucero; Ana Gonzalo; Aurelio Orjales; Rosario Calvo
Journal:  Pharm Res       Date:  2005-09-20       Impact factor: 4.200

3.  Deterministic identifiability of population pharmacokinetic and pharmacokinetic-pharmacodynamic models.

Authors:  Vijay K Siripuram; Daniel F B Wright; Murray L Barclay; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-06-13       Impact factor: 2.745

4.  Structural identifiability analysis of pharmacokinetic models using DAISY: semi-mechanistic gastric emptying models for 13C-octanoic acid.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-02-24       Impact factor: 2.745

5.  Steady-state population pharmacokinetics of terizidone and its metabolite cycloserine in patients with drug-resistant tuberculosis.

Authors:  Mwila Mulubwa; Pierre Mugabo
Journal:  Br J Clin Pharmacol       Date:  2019-07-12       Impact factor: 4.335

6.  Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis.

Authors:  J A Webb; A Rostami-Hodjegan; R Abdul-Manap; U Hofmann; G Mikus; F Kamali
Journal:  Br J Clin Pharmacol       Date:  2001-07       Impact factor: 4.335

7.  Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition.

Authors:  A A Moghadamnia; A Rostami-Hodjegan; R Abdul-Manap; C E Wright; A H Morice; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

8.  Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9.

Authors:  Zheng Jiao; Jun-Jie Ding; Jie Shen; Hui-Qi Liang; Long-Jin Zhong; Yi Wang; Ming-Kang Zhong; Wei-Yue Lu
Journal:  Br J Clin Pharmacol       Date:  2008-02-15       Impact factor: 4.335

9.  Simultaneous pharmacokinetic model for rolofylline and both M1-trans and M1-cis metabolites.

Authors:  Mark Stroh; Matthew M Hutmacher; Jianmei Pang; Ryan Lutz; Hiroshi Magara; Julie Stone
Journal:  AAPS J       Date:  2013-01-25       Impact factor: 4.009

10.  Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.

Authors:  Rob ter Heine; Lisette Binkhorst; Anne Joy M de Graan; Peter de Bruijn; Jos H Beijnen; Ron H J Mathijssen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.